# Sacituzumab govitecan

## Trodelvy inj 180mg

| TAH Drug Code      | [ITRO](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ITRO)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | ‧ Indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior systemic therapies， including at least one for advanced disease. ‧ Indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive， human epidermal growth factor receptor 2 (HER2)-negative (IHC 0， IHC 1+， or IHC 2+/ISH–) breast cancer who have received at least two prior systemic therapies for metastatic disease.                                                                                                                                                     |
| Dosing             | Recommended dose: 10 mg/kg， not exceeding 10 mg/kg. Administer via intravenous infusion on Days 1 and 8 of a 21-day cycle. Continue treatment until disease progression or unacceptable toxicity. Only use intravenous infusion; no bolus or push administration. Initial infusion: Over 3 hours with 30-minute post-infusion observation. Subsequent infusions: May be infused over 1 to 2 hours or longer if tolerated， with 30-minute post-infusion observation.                                                                                                                                                                                                                                                       |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Severe hypersensitivity reaction to sacituzumab govitecan.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Adverse Effects    | Common: Alopecia (38-49%)， Rash (12-32%)， Abdominal pain (20-31%)， Constipation (34-37%)， Decrease in appetite (21-41%)， Diarrhea， All Grades (59-72%)， Inflammatory disease of mucous membrane (14%)， Nausea， All Grades (57-69%)， Vomiting， All Grades (23-49%)， Neutropenia， All Grades (64%)， Fatigue (51-68%) Serious: Diarrhea， Grade 3 or 4 (9-12%)， Nausea， Grade 3 or 4 (1-6%)， Perforation of intestine (0.09%)， Vomiting， Grade 3 or 4 (1-6%)， Anemia， Grade 3 or 4 (9-21%)， Febrile neutropenia (6-7%)， Neutropenia， Grade 3 or 4 (43-58%)， Anaphylaxis (0.2%)， Hypersensitivity reaction (35%)， Suicide， Pneumonia (4%)， Respiratory failure， Respiratory tract infection (26%) |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sacituzumab-govitecan-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

